IN2014DN05986A - - Google Patents
Info
- Publication number
- IN2014DN05986A IN2014DN05986A IN5986DEN2014A IN2014DN05986A IN 2014DN05986 A IN2014DN05986 A IN 2014DN05986A IN 5986DEN2014 A IN5986DEN2014 A IN 5986DEN2014A IN 2014DN05986 A IN2014DN05986 A IN 2014DN05986A
- Authority
- IN
- India
- Prior art keywords
- idh1
- administering
- treating
- subject
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012070601 | 2012-01-19 | ||
PCT/CN2013/000068 WO2013107291A1 (en) | 2012-01-19 | 2013-01-21 | Therapeutically active compounds and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN05986A true IN2014DN05986A (ja) | 2015-06-26 |
Family
ID=48797706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5986DEN2014 IN2014DN05986A (ja) | 2012-01-19 | 2013-01-21 |
Country Status (41)
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2755394C (en) | 2009-03-13 | 2021-10-19 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2011002817A1 (en) | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
ES2675903T3 (es) | 2011-05-03 | 2018-07-13 | Agios Pharmaceuticals, Inc. | Activadores de piruvato quinasa para uso en terapia |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN107417667B (zh) | 2012-01-06 | 2020-04-10 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
MX350432B (es) * | 2012-01-19 | 2017-09-06 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de empleo. |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
CA2888360A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
JP6529492B2 (ja) | 2013-07-11 | 2019-06-12 | アジオス ファーマシューティカルズ, インコーポレイテッド | 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物 |
BR112016000489A8 (pt) | 2013-07-11 | 2020-01-07 | Agios Pharmaceuticals Inc | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015010297A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN103694142A (zh) * | 2013-11-28 | 2014-04-02 | 浙江科技学院 | 4-N-Boc-氨基环己酮的制备方法 |
WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
EA034366B1 (ru) * | 2014-03-14 | 2020-01-31 | Аджиос Фармасьютикалз, Инк | Способ лечения распространённых солидных опухолей с помощью ингибитора idh1 |
DK3177612T3 (da) | 2014-08-04 | 2022-05-16 | Nuevolution As | Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme |
MX2017003782A (es) | 2014-10-01 | 2017-08-10 | Daiichi Sankyo Co Ltd | Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante. |
MX2017016041A (es) | 2015-06-11 | 2018-04-24 | Agios Pharmaceuticals Inc | Metodos para usar activadores de piruvato cinasa. |
MX2018004587A (es) | 2015-10-15 | 2018-08-14 | Agios Pharmaceuticals Inc | Terapia de combinacion para tratar tumores malignos. |
BR112018007656A2 (pt) * | 2015-10-15 | 2018-11-06 | Agios Pharmaceuticals Inc | terapia de combinação para tratamento de doenças malignas |
EA039805B1 (ru) * | 2015-11-13 | 2022-03-15 | Аджиос Фармасьютикалз, Инк. | Комбинированная терапия для лечения злокачественных опухолей |
JP6892448B2 (ja) * | 2015-12-04 | 2021-06-23 | アジオス ファーマシューティカルズ, インコーポレイテッド | 悪性腫瘍の処置の方法 |
WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
MX2018010252A (es) | 2016-02-26 | 2019-01-31 | Celgene Corp | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. |
WO2017162157A1 (zh) * | 2016-03-22 | 2017-09-28 | 正大天晴药业集团股份有限公司 | 内磺酰胺化合物及其使用方法 |
WO2018010142A1 (en) | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
SG11201901747VA (en) | 2016-08-31 | 2019-03-28 | Agios Pharmaceuticals Inc | Inhibitors of cellular metabolic processes |
KR20200015745A (ko) | 2017-06-12 | 2020-02-12 | 아지오스 파마슈티컬스 아이엔씨. | 병용 요법을 사용한 뇌 종양 치료 방법 |
AU2018284104A1 (en) * | 2017-06-12 | 2020-01-16 | Les Laboratories Servier | Methods of treating brain tumors using combination therapy |
CN111065630B (zh) * | 2017-09-22 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种内磺酰胺化合物结晶 |
EP3717470A1 (en) | 2017-11-27 | 2020-10-07 | Assia Chemical Industries Ltd | Solid state forms of ivosidenib |
WO2019161383A1 (en) * | 2018-02-19 | 2019-08-22 | The Regents Of The University Of Colorado, A Body Corporate | Oxopiperidine quantitation by mass spectrometry |
WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
EP3720442B1 (en) | 2018-05-16 | 2022-12-28 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
US10980788B2 (en) * | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
WO2020010058A1 (en) | 2018-07-06 | 2020-01-09 | Agios Pharmaceuticals, Inc. | Ivosidenib forms and pharmaceutical compositions |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
CN109535025B (zh) * | 2018-12-18 | 2022-09-09 | 尚科生物医药(上海)有限公司 | 一种艾伏尼布中间体3,3-二氟环丁胺盐酸盐的制备方法 |
WO2020127887A1 (en) | 2018-12-21 | 2020-06-25 | Sandoz Ag | Process for the preparation of an intermediate product of ivosidenib |
FI4010331T3 (fi) | 2019-08-08 | 2023-12-28 | Servier Lab | Menetelmä ivosidenibin ja sen välituotteen valmistamiseksi |
ES2965468T3 (es) * | 2019-08-09 | 2024-04-15 | Artios Pharma Ltd | Compuestos heterocíclicos para uso en el tratamiento del cáncer |
TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
WO2021028791A1 (en) * | 2019-08-09 | 2021-02-18 | Alembic Pharmaceuticals Limited | An improved process of preparation of ivosidenib |
WO2021079380A1 (en) * | 2019-10-23 | 2021-04-29 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of (2s)-n-{(1s)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN111349081B (zh) * | 2020-04-28 | 2021-01-15 | 宁波大学科学技术学院 | 一种Ivosidenib及其中间体的手性合成方法 |
AU2021311539A1 (en) | 2020-07-21 | 2023-02-09 | Daiichi Sankyo Company, Limited | Combination drug of temozolomide and inhibitor of mutated IDH1 enzyme |
TW202330491A (zh) * | 2021-12-30 | 2023-08-01 | 大陸商上海湃隆生物科技有限公司 | 一種DNA聚合酶theta抑制劑及其應用 |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
NL125847C (ja) | 1963-02-15 | |||
BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3867383A (en) | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
BE793501A (fr) | 1971-12-31 | 1973-06-29 | Ciba Geigy | Composes heterocycliques et produits phytopharmaceutiques qui en contiennent |
CH606334A5 (ja) | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
US5041443A (en) | 1989-02-21 | 1991-08-20 | Dainippon Pharmaceutical Co., Ltd. | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof |
US5021421A (en) | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
JPH0491034A (ja) | 1990-08-02 | 1992-03-24 | Fujimoto Daiagunosuteitsukusu:Kk | 中枢神経保護剤 |
JPH0499768A (ja) | 1990-08-17 | 1992-03-31 | Dainippon Pharmaceut Co Ltd | 4―(4―フェニルピリジン―2―イル)ピペラジン―1―オキシド誘導体 |
JPH05140126A (ja) | 1991-11-26 | 1993-06-08 | Hokko Chem Ind Co Ltd | トリアゾール誘導体および除草剤 |
WO1993017009A1 (en) | 1992-02-28 | 1993-09-02 | Zenyaku Kogyo Kabushiki Kaisha | s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
FR2735127B1 (fr) | 1995-06-09 | 1997-08-22 | Pf Medicament | Nouvelles piperazines heteroaromatiques utiles comme medicaments. |
ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
US6313127B1 (en) | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
BR9709105A (pt) | 1996-05-20 | 1999-08-03 | Darwin Discovery Ltd | Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv |
US5984882A (en) | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
EP0945446A4 (en) | 1996-11-14 | 1999-12-08 | Nissan Chemical Ind Ltd | CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME |
US6399358B1 (en) | 1997-03-31 | 2002-06-04 | Thomas Jefferson University | Human gene encoding human chondroitin 6-sulfotransferase |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
DE1042305T1 (de) | 1997-12-22 | 2001-04-19 | Bayer Ag | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
AU9064598A (en) | 1998-07-10 | 2000-02-01 | Harald Groger | Precusors for pna-monomers |
PT1588716E (pt) | 1998-08-06 | 2011-05-25 | Mountain View Pharmaceuticals | Conjugados de peg-urato oxidase e sua utiliza??o |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
AU5379900A (en) | 1999-06-07 | 2000-12-28 | Shire Biochem Inc. | Thiophene integrin inhibitors |
AU775625B2 (en) | 1999-08-27 | 2004-08-05 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
DE60043397D1 (de) | 1999-12-28 | 2010-01-07 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
ATE311366T1 (de) | 2000-02-29 | 2005-12-15 | Millennium Pharm Inc | Benzamide und ähnliche inhibitoren vom faktor xa |
WO2002008221A2 (en) | 2000-07-20 | 2002-01-31 | Neurogen Corporation | Capsaicin receptor ligands |
JP4113323B2 (ja) | 2000-08-07 | 2008-07-09 | 富士フイルム株式会社 | アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法 |
US6525091B2 (en) | 2001-03-07 | 2003-02-25 | Telik, Inc. | Substituted diarylureas as stimulators for Fas-mediated apoptosis |
US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
EA008476B1 (ru) | 2001-06-11 | 2007-06-29 | Биовитрум Аб | Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii |
EP1397142A4 (en) | 2001-06-19 | 2004-11-03 | Bristol Myers Squibb Co | PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7 |
DK1423371T3 (da) | 2001-08-17 | 2011-02-07 | Basf Se | Triazinderivater og anvendelse deraf som solbeskyttelse |
JP4753336B2 (ja) | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
US20040067234A1 (en) | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
AU2003259153A1 (en) | 2002-07-18 | 2004-02-09 | Alan Deangelis | Substituted triazine kinase inhibitors |
JP2004083610A (ja) | 2002-08-22 | 2004-03-18 | Fuji Photo Film Co Ltd | インクセット、インクカートリッジ、記録方法、プリンター及び記録物 |
JP2004107220A (ja) | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | TNF−α産生抑制剤 |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
WO2004050033A2 (en) | 2002-12-02 | 2004-06-17 | Arqule, Inc. | Method of treating cancers |
ES2373947T3 (es) | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
EP1587519A4 (en) | 2003-01-10 | 2006-05-31 | Threshold Pharmaceuticals Inc | TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE |
US7358262B2 (en) | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
WO2004074438A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
JP4629657B2 (ja) | 2003-04-11 | 2011-02-09 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物 |
PE20050338A1 (es) | 2003-08-06 | 2005-05-16 | Vertex Pharma | Compuestos de aminotriazoles como inhibidores de proteina quinasas |
JP4948173B2 (ja) | 2003-10-10 | 2012-06-06 | ニツポネツクス・インコーポレーテツド | 過剰増殖性疾患治療用ピリミジン誘導体 |
JP4099768B2 (ja) | 2003-11-10 | 2008-06-11 | 富士電機デバイステクノロジー株式会社 | 電子写真感光体および該電子写真感光体に起因する干渉縞有無の判定方法 |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
WO2005065691A1 (en) | 2003-12-24 | 2005-07-21 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
JP2005264016A (ja) | 2004-03-19 | 2005-09-29 | Fuji Photo Film Co Ltd | インクジェット記録用インク、インクセット及びインクジェット記録方法 |
US7335770B2 (en) | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
GB0412526D0 (en) | 2004-06-05 | 2004-07-14 | Leuven K U Res & Dev | Type 2 diabetes |
CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
EP1924573A1 (en) | 2005-01-25 | 2008-05-28 | AstraZeneca AB | B-raf inhibitors |
SG2014009484A (en) | 2005-04-11 | 2014-05-29 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
WO2006133420A2 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Treatment of patients with cancer therapy |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
WO2007023186A1 (en) | 2005-08-26 | 2007-03-01 | Laboratoires Serono S.A. | Pyrazine derivatives and use as pi3k inhibitors |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
WO2008036835A2 (en) | 2006-09-20 | 2008-03-27 | Reddy Us Therapeutics | Methods and compositions for upregulation of peroxiredoxin activity |
US20080109846A1 (en) | 2006-10-23 | 2008-05-08 | Ewertz C Christian | System and method for audiovisual content playback |
US7906555B2 (en) | 2006-10-26 | 2011-03-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
JP2010511727A (ja) | 2006-12-04 | 2010-04-15 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | アデノシン受容体アンタゴニストとしての置換ピリミジン |
SG10201504425SA (en) | 2006-12-08 | 2015-07-30 | Millennium Pharm Inc | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
EP2120964A2 (en) | 2006-12-15 | 2009-11-25 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
WO2008131547A1 (en) | 2007-04-30 | 2008-11-06 | Prometic Biosciences Inc. | 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives' |
JP2010529193A (ja) | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
AU2008280283B2 (en) | 2007-07-20 | 2013-11-07 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
TW200906818A (en) | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
CN101981010A (zh) | 2007-10-10 | 2011-02-23 | 武田药品工业株式会社 | 酰胺化合物 |
WO2009051910A1 (en) * | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
JP5277685B2 (ja) | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
HUE064677T2 (hu) | 2008-05-15 | 2024-04-28 | Celgene Corp | Citidin-analógokat tartalmazó orális készítmények és eljárások azok alkalmazására |
FR2932483A1 (fr) | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
TW201028381A (en) | 2008-07-14 | 2010-08-01 | Shionogi & Co | Pyridine derivative having ttk inhibition activity |
EP2546365B1 (en) | 2008-09-03 | 2016-11-09 | The Johns Hopkins University | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma |
WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
JP2010079130A (ja) | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
EP2370417A2 (en) | 2008-11-21 | 2011-10-05 | Millennium Pharmaceuticals, Inc. | Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
JP2010181540A (ja) | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
WO2010090290A1 (ja) | 2009-02-06 | 2010-08-12 | 日本新薬株式会社 | アミノピラジン誘導体及び医薬 |
CA2755394C (en) | 2009-03-13 | 2021-10-19 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
ES2619557T3 (es) | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 para uso en el tratamiento del cáncer |
WO2010130638A1 (en) | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
CA2764785C (en) | 2009-06-08 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
EP2440054A4 (en) | 2009-06-09 | 2012-12-12 | California Capital Equity Llc | PYRIDILTRIA INHIBITOR OF HEDGEHOG SIGNALING |
EP2440056A4 (en) | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | DERIVATIVES OF UREIDOPHENYL SUBSTITUTED TRIAZINE AND THERAPEUTIC APPLICATIONS THEREOF |
WO2011002817A1 (en) | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2011005208A1 (en) | 2009-07-10 | 2011-01-13 | Milux Holding S.A. | Knee joint device and method |
CA2772194A1 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
US20120189670A1 (en) | 2009-09-14 | 2012-07-26 | Kirkpatrick D Lynn | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
JP5473851B2 (ja) | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
US8652534B2 (en) | 2009-10-14 | 2014-02-18 | Berry Pharmaceuticals, LLC | Compositions and methods for treatment of mammalian skin |
ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
SG10201501272SA (en) | 2009-10-22 | 2015-04-29 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
ES2642109T3 (es) | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
NZ578968A (en) | 2010-02-10 | 2011-03-31 | Allans Sheetmetal And Engineering Services | Fuel feed system for a pellet fire |
US20130197106A1 (en) | 2010-04-01 | 2013-08-01 | Agios Pharmaceuticals, Inc | Methods of identifying a candidate compound |
WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
JP6081354B2 (ja) | 2010-07-16 | 2017-02-15 | アジオス ファーマシューティカルズ, インコーポレイテッド | 治療活性組成物およびそれらの使用方法 |
SI2630146T1 (sl) | 2010-10-21 | 2020-12-31 | Medivation Technologies Llc | Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON |
WO2012078288A2 (en) | 2010-11-08 | 2012-06-14 | Washington University | Methods of determining risk of adverse outcomes in acute myeloid leukemia |
JP5907986B2 (ja) | 2010-11-29 | 2016-04-26 | ガリオン ファーマシューティカルズ インコーポレイテッド | 呼吸制御障害または呼吸制御疾患の処置用の呼吸刺激薬としての化合物 |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO ISOCITRATE DEHYDROGENASE |
CA2834692A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
CA2834610A1 (en) | 2011-06-06 | 2012-12-13 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
AU2012280725B2 (en) | 2011-07-07 | 2017-02-02 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
ES2627120T3 (es) | 2011-07-08 | 2017-07-26 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicamento para el tratamiento del cáncer de hígado |
EP2734519B1 (en) | 2011-07-22 | 2016-05-04 | University Of Louisville Research Foundation, Inc. | Anti-biofilm compounds |
MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
CN102659765B (zh) | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
CN107417667B (zh) | 2012-01-06 | 2020-04-10 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
MX350432B (es) | 2012-01-19 | 2017-09-06 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de empleo. |
EP2634259A1 (en) | 2012-03-01 | 2013-09-04 | Deutsches Krebsforschungszentrum | Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG) |
US20150011751A1 (en) | 2012-03-09 | 2015-01-08 | Carna Biosciences, Inc. | Novel triazine derivative |
WO2014015422A1 (en) | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
CA2888360A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015127173A1 (en) | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
EA034366B1 (ru) | 2014-03-14 | 2020-01-31 | Аджиос Фармасьютикалз, Инк | Способ лечения распространённых солидных опухолей с помощью ингибитора idh1 |
KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
MX2018004587A (es) | 2015-10-15 | 2018-08-14 | Agios Pharmaceuticals Inc | Terapia de combinacion para tratar tumores malignos. |
BR112018007656A2 (pt) | 2015-10-15 | 2018-11-06 | Agios Pharmaceuticals Inc | terapia de combinação para tratamento de doenças malignas |
JP6892448B2 (ja) | 2015-12-04 | 2021-06-23 | アジオス ファーマシューティカルズ, インコーポレイテッド | 悪性腫瘍の処置の方法 |
MX2018010252A (es) | 2016-02-26 | 2019-01-31 | Celgene Corp | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. |
-
2013
- 2013-01-18 US US13/745,005 patent/US9474779B2/en active Active
- 2013-01-21 SI SI201331959T patent/SI3447052T1/sl unknown
- 2013-01-21 NZ NZ722400A patent/NZ722400A/en unknown
- 2013-01-21 ES ES13738319.6T patent/ES2685746T3/es active Active
- 2013-01-21 PL PL13738319T patent/PL2804851T3/pl unknown
- 2013-01-21 DK DK18183579.4T patent/DK3447052T3/da active
- 2013-01-21 UA UAA201409238A patent/UA115047C2/uk unknown
- 2013-01-21 WO PCT/CN2013/000068 patent/WO2013107291A1/en active Application Filing
- 2013-01-21 HR HRP20220017TT patent/HRP20220017T1/hr unknown
- 2013-01-21 EP EP21203128.0A patent/EP3985001A1/en active Pending
- 2013-01-21 PL PL18183579T patent/PL3447052T3/pl unknown
- 2013-01-21 AU AU2013211436A patent/AU2013211436B2/en active Active
- 2013-01-21 UA UAA201700262A patent/UA122324C2/uk unknown
- 2013-01-21 KR KR1020147022964A patent/KR102044730B1/ko active IP Right Grant
- 2013-01-21 MX MX2014008744A patent/MX351166B/es active IP Right Grant
- 2013-01-21 EA EA201491391A patent/EA026723B1/ru unknown
- 2013-01-21 RS RS20220030A patent/RS62919B1/sr unknown
- 2013-01-21 AR ARP130100177A patent/AR089768A1/es active IP Right Grant
- 2013-01-21 CA CA3077245A patent/CA3077245A1/en not_active Abandoned
- 2013-01-21 KR KR1020197033106A patent/KR102108507B1/ko active IP Right Grant
- 2013-01-21 CR CR20170097A patent/CR20170097A/es unknown
- 2013-01-21 PT PT181835794T patent/PT3447052T/pt unknown
- 2013-01-21 CA CA2861556A patent/CA2861556C/en active Active
- 2013-01-21 NZ NZ627053A patent/NZ627053A/en unknown
- 2013-01-21 DK DK13738319.6T patent/DK2804851T3/en active
- 2013-01-21 CN CN201610805857.XA patent/CN106496090B/zh active Active
- 2013-01-21 LT LTEP18183579.4T patent/LT3447052T/lt unknown
- 2013-01-21 TW TW107116320A patent/TWI713847B/zh active
- 2013-01-21 BR BR112014017840-2A patent/BR112014017840B1/pt active IP Right Grant
- 2013-01-21 HU HUE13738319A patent/HUE039110T2/hu unknown
- 2013-01-21 HU HUE18183579A patent/HUE057264T2/hu unknown
- 2013-01-21 PE PE2019000472A patent/PE20190801A1/es not_active Application Discontinuation
- 2013-01-21 TW TW102102190A patent/TWI636040B/zh active
- 2013-01-21 SG SG11201404190PA patent/SG11201404190PA/en unknown
- 2013-01-21 ES ES18183579T patent/ES2903390T3/es active Active
- 2013-01-21 JP JP2014552489A patent/JP6313714B2/ja active Active
- 2013-01-21 KR KR1020207012665A patent/KR102144739B1/ko active IP Right Grant
- 2013-01-21 IN IN5986DEN2014 patent/IN2014DN05986A/en unknown
- 2013-01-21 MY MYPI2014002104A patent/MY178486A/en unknown
- 2013-01-21 EP EP18183579.4A patent/EP3447052B1/en active Active
- 2013-01-21 RS RS20181025A patent/RS57730B1/sr unknown
- 2013-01-21 LT LTEP13738319.6T patent/LT2804851T/lt unknown
- 2013-01-21 EA EA201692271A patent/EA035662B1/ru unknown
- 2013-01-21 EP EP13738319.6A patent/EP2804851B1/en active Active
- 2013-01-21 SG SG10202103521PA patent/SG10202103521PA/en unknown
- 2013-01-21 SI SI201331138T patent/SI2804851T1/sl unknown
- 2013-01-21 PT PT13738319T patent/PT2804851T/pt unknown
- 2013-01-21 SG SG10201608374XA patent/SG10201608374XA/en unknown
- 2013-01-21 PE PE2014001128A patent/PE20141824A1/es active IP Right Grant
- 2013-01-21 CN CN201380009364.XA patent/CN104136411B/zh active Active
-
2014
- 2014-07-15 PH PH12014501626A patent/PH12014501626B1/en unknown
- 2014-07-17 CL CL2014001891A patent/CL2014001891A1/es unknown
- 2014-07-17 IL IL233683A patent/IL233683B/en active IP Right Grant
- 2014-07-18 CO CO14156115A patent/CO7010834A2/es unknown
- 2014-07-18 NI NI201400078A patent/NI201400078A/es unknown
- 2014-08-18 EC ECIEPI201414544A patent/ECSP14014544A/es unknown
- 2014-08-18 CR CR20140388A patent/CR20140388A/es unknown
- 2014-11-26 HK HK14111932.2A patent/HK1198439A1/xx unknown
-
2016
- 2016-01-05 US US14/988,661 patent/US20160130298A1/en not_active Abandoned
- 2016-09-28 US US15/279,146 patent/US9850277B2/en active Active
-
2017
- 2017-02-28 JP JP2017036691A patent/JP2017101067A/ja not_active Withdrawn
- 2017-08-08 PH PH12017501419A patent/PH12017501419B1/en unknown
- 2017-11-10 US US15/809,325 patent/US10640534B2/en active Active
- 2017-11-23 AU AU2017265100A patent/AU2017265100B2/en active Active
-
2018
- 2018-06-29 PH PH12018501410A patent/PH12018501410A1/en unknown
- 2018-07-27 HR HRP20181199TT patent/HRP20181199T1/hr unknown
- 2018-09-04 CY CY181100915T patent/CY1120651T1/el unknown
- 2018-11-02 JP JP2018207185A patent/JP6805220B2/ja active Active
-
2019
- 2019-01-28 IL IL264516A patent/IL264516B/en active IP Right Grant
- 2019-05-31 US US16/427,691 patent/US10717764B2/en active Active
- 2019-12-19 AU AU2019283951A patent/AU2019283951B2/en active Active
-
2020
- 2020-06-05 US US16/893,750 patent/US11667673B2/en active Active
- 2020-11-30 JP JP2020198026A patent/JP2021038263A/ja not_active Withdrawn
-
2021
- 2021-01-19 ZA ZA2021/00373A patent/ZA202100373B/en unknown
- 2021-03-31 IL IL281942A patent/IL281942B/en unknown
- 2021-07-07 AR ARP210101907A patent/AR122902A2/es unknown
-
2022
- 2022-01-19 CY CY20221100045T patent/CY1124988T1/el unknown
-
2023
- 2023-02-17 US US18/111,511 patent/US20240059733A1/en active Pending
- 2023-09-07 FR FR23C1031C patent/FR23C1031I1/fr active Active
- 2023-09-18 NL NL301243C patent/NL301243I2/nl unknown
- 2023-10-10 HU HUS2300035C patent/HUS2300035I1/hu unknown
- 2023-10-10 FI FIC20230031C patent/FIC20230031I1/fi unknown
- 2023-10-27 CY CY2023023C patent/CY2023023I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN05986A (ja) | ||
MX350432B (es) | Compuestos terapeuticamente activos y sus metodos de empleo. | |
MX342951B (es) | Composiciones terapeuticamente activas y su metodo de uso. | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
MX2021001425A (es) | Compuestos terapeuticos activos y sus usos. | |
IN2015DN00438A (ja) | ||
EA201400178A1 (ru) | Лечение рака молочной железы | |
MY177300A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
NZ710740A (en) | Glycopyrrolate salts | |
GB2498325A (en) | Modulation neural pathways | |
NZ628433A (en) | Chitosan-derived compositions | |
IN2014DN11078A (ja) | ||
MX2013003599A (es) | Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer. | |
MX2016007982A (es) | Nuevo compuesto para el tratamiento de hipoglucemia severa. | |
IN2014DN07191A (ja) | ||
IN2014KN01772A (ja) | ||
IN2015KN00676A (ja) | ||
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
TN2011000545A1 (en) | Vinyl indazolyl compounds | |
UA72478U (ru) | Применение полентара как средства фригопротекторного действия | |
UA76841U (en) | Feed additive "echinobioactive" | |
UA80618U (en) | Use of n-steroylethanolamine as radiomodifier |